Teitur shares promising early trial results for Parkinson's peptide TT P34

A Danish biotechnology company called Teitur Trophics has just shared encouraging news about an experimental molecule called TT P34. In a small first stage clinical trial, the once weekly injection proved safe, reached deep into the brain, and showed signs of waking up vital cellular cleanup systems. Getting new treatments into the brain is notoriously tricky because natural biological barriers block most medicines from crossing over. TT P34 managed to slip past that barrier with ease. Testing in sixty seven participants at a specialised research centre in Leiden confirmed that higher doses led to higher levels of the drug reaching the central nervous system, all without serious side effects. It even worked safely alongside standard levodopa therapy. Inside brain cells, two tiny structures do the heavy lifting. Mitochondria create everyday energy, while lysosomes act like microscopic recycling plants that break down biological waste. When these recycling plants slow down, cellular rubbish builds up and cells struggle to survive. TT P34 is built to kickstart both systems at once. Spinal fluid samples taken over fifty days showed clear changes in key proteins linked to that cellular waste disposal system. This gives scientists strong early evidence that the drug is doing exactly what it was designed to do in people living with the condition. The researchers will present their complete findings in Seoul next month, with plans already underway to launch a larger phase two trial in 2027 to see if these cellular changes can help slow progression.